Monday morning brought more hopeful news about a coronavirus vaccine, this time from Moderna. The company announced that its candidate, still in late-stage trials, appears to be 94.5% effective. That's even better than the 90% rate reported by Pfizer last week. Related coverage:
- First doses: Moderna is on track to win FDA approval and have 20 million doses ready for Americans by year's end, reports the Wall Street Journal. This is a two-dose vaccine, meaning that's enough for 10 million people. Pfizer (also a two-dose vaccine) has previously said it expected to have 50 million doses by year's end, per the New York Times. The federal government will help determine who gets the first shots, but front-line health workers and first responders are expected to be among them.